AVANIR Pharmaceuticals to Announce Fourth Fiscal Quarter And Year-End 2002 Results on December 19

SAN DIEGO, Dec. 17 /PRNewswire-FirstCall/ -- AVANIR Pharmaceuticals (Amex: AVN - News) will announce financial results for the fourth fiscal quarter and year ended September 30, 2002 on Thursday, December 19, 2002.

Following the release, management will host a conference call with a simultaneous webcast at 8:00 a.m. Pacific/ 11:00 a.m. Eastern to discuss fourth fiscal quarter and year-end 2002 operating performance and outlook. The webcast, featuring President and Chief Executive Officer Gerald J. Yakatan, Ph.D. and Vice President and Chief Financial Officer Gregory Hanson, will be available live via the Internet by accessing AVANIR's web site at www.avanir.com . The live webcast will also be available at CCBN's www.companyboardroom.com . Please go to either web site at least ten minutes early to register, download and install any necessary audio software.

For those who cannot listen to the live broadcast, the online replays will be available for 90 days, or a phone replay will be available through December 26, 2002, by dialing (888) 266-2086 and entering the passcode # 6358325.

AVANIR Pharmaceuticals, based in San Diego, is engaged in research, discovery and development of innovative drug products for chronic diseases and, through its subsidiary Xenerex Biosciences, antibody generation services. Further information about AVANIR and Xenerex can be found at www.avanir.com .

AVANIR press releases, including any forward-looking statements contained therein, should be reviewed in conjunction with the company's Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect." Research findings are not always supportable by evidence obtained from subsequent clinical trials. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.

For further information, please contact: general, Kristen McNally, +1-310-407-6548, kmcnally@webershandwick.com , or investors, Tricia Ross, +1-310-407-6540, tross@webershandwick.com , or media, Tim Grace, +1-312-640-6667, tgrace@webershandwick.com , all of FRB | Weber Shandwick, for AVANIR Pharmaceuticals; or investors, Patrice Saxon of AVANIR Pharmaceuticals, +1-858-622-5202, psaxon@avanir.com .